Bionano to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIA
12 Janeiro 2023 - 10:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a
collaboration with NVIDIA to develop an acceleration platform for
use in Bionano’s optical genome mapping (OGM) workflow. This
collaboration is expected to significantly improve data processing
speed while reducing time and cost associated with secondary
analysis of OGM data. The computation platform is designed to
enable a small laboratory and information technology footprint,
which would allow for rapid decentralized deployment.
By combining NVIDIA’s expertise in accelerated computing and the
capabilities of the NVIDIA RTX™ 6000 Ada Generation professional
GPU with Bionano’s knowledge in extraction, enzymatic treatment,
and analysis of ultra-high molecular weight (UHMW) DNA molecules,
the collaboration aims to develop on-premise and cloud-based
solutions to keep pace with the anticipated data generation needs
of high-throughput OGM workflows. The collaborative solution is
projected to support analysis of 96 cancer workflows or just over
300 constitutional whole genomes per week and be integrated with
Bionano’s NxClinical™ software for variant interpretation and
reporting.
Bionano will preview the solution with NVIDIA at the Advances in
Genome Biology and Technology (AGBT) General Meeting, which will
take place February 6-9, 2023, in Hollywood, Florida.
“Bionano is focused on continuous upscaling of our end-to-end
genome mapping solutions, and we see this collaboration with NVIDIA
as an important part of that effort,” said Erik Holmlin, PhD,
president and chief executive officer of Bionano Genomics. “We
believe the solution we’re developing with NVIDIA will accelerate
OGM analysis and enable future expansion into areas including CAR
T-cell therapy research and bioprocessing.”
“Bionano’s optical genome mapping platform provides tremendous
capability for genome-wide structural variant detection, which can
have huge impact for cancer research and other areas of human
health,” said George Vacek, global head of genomics alliances at
NVIDIA. “By accelerating Bionano’s analysis, we will help achieve
higher throughput in a smaller footprint at lower cost, enabling
the application of this technology to new areas, both at scale and
in smaller labs.”
About Bionano Genomics, Inc.Bionano Genomics is
a provider of genome analysis solutions that can enable researchers
and clinicians to reveal answers to challenging questions in
biology and medicine. The Company’s mission is to transform the way
the world sees the genome through OGM solutions, diagnostic
services and software. The Company offers OGM solutions for
applications across basic, translational and clinical research.
Through its Lineagen business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com,
www.lineagen.com or www.biodiscovery.com
Bionano’s OGM products are for research use only and not for use
in diagnostic procedures.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “can,” “expect,” “would,” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the anticipated benefits and improvements in
the secondary analysis of OGM data resulting from the platform
expected to be developed in collaboration with NVIDIA and Bionano,
or the ability of the platform to reliably and consistently improve
data processing speed while reducing time and cost associated with
secondary analysis of OGM data. Each of these forward-looking
statements involves risks and uncertainties. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with:
global and macroeconomic events, such as the impact of the COVID-19
pandemic and the ongoing Ukraine-Russian conflict and related
sanctions; general market conditions; changes in the competitive
landscape and the introduction of competitive technologies or
improvements in existing technologies; failure of the platform to
reliably and consistently improve data processing speed while
reducing time and cost associated with secondary analysis of OGM
data; failure of NVIDIA and Bionano to complete development or
commercial introduction of the platform contemplated in this press
release; changes in our strategic and commercial plans; our ability
to obtain sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2021
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024